News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
byStephen Padilla
The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.
17 Jan 2026

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
byStephen Padilla
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.
16 Jan 2026







